CCL22-based peptide vaccines induce anti-cancer immunity by modulating tumor microenvironment

Autor: Inés Lecoq, Katharina L. Kopp, Marion Chapellier, Panagiotis Mantas, Evelina Martinenaite, Maria Perez-Penco, Lars Rønn Olsen, Mai-Britt Zocca, Ayako Wakatsuki Pedersen, Mads Hald Andersen

Publikováno v: OncoImmunology, Vol 11, Iss 1 (2022)

CCL22 is a macrophage-derived immunosuppressive chemokine that recruits regulatory T cells through the CCL22:CCR4 axis. CCL22 was shown to play a key role in suppressing anti-cancer immune responses in different cancer types. Recently, we showed that

Externí odkaz: https://doaj.org/article/4deb28186bcd4fa28e4ce8cd2df20145

Arginase 1-Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Anti-PD-1 Checkpoint Blockade

Autor: Evelina Martinenaite, Annalisa Adamo, Stine Emilie Weis-Banke, Katharina L. Kopp, Maria Perez-Penco, Stefano Ugel, Marion Chapellier, Vincenzo Bronte, Mie Linder Hübbe, Cristina Frusteri, Marco Carretta, Mia Aaboe Jørgensen, Mai-Britt Zocca, Francesco De Sanctis, Ayako Wakatsuki Pedersen, Manuela Iezzi, Mads Hald Andersen, Daniel Hargbøll Madsen

Publikováno v: Cancer immunology research. 9(11)

Expression of the L-arginine catabolizing enzyme arginase 1 (ARG1) is a central immunosuppressive mechanism mediated by tumor-educated myeloid cells. Increased activity of ARG1 promotes the formation of an immunosuppressive microenvironment and leads

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f5c10fa0f3c105df278cfbbbc391be1
https://pubmed.ncbi.nlm.nih.gov/34518197

P09.07 An immune modulatory vaccine targeting CCL22 promotes anti-tumor immunity

Autor: R Christensen, Ayako Wakatsuki Pedersen, Inés Lecoq, Katharina L. Kopp, Mads Hald Andersen, Evelina Martinenaite

Publikováno v: E-Poster Presentations.

Background CCL22 is a macrophage-derived chemokine that exerts immunosuppressive functions by the recruitment of regulatory T cells (Treg) through the CCL22/CCR4 axis. It has been described to play a key role in the suppression of anti-cancer immunit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0e5c9f82c9aad77799374ecc354c315b
https://doi.org/10.1136/jitc-2020-itoc7.107

Peptide vaccination directed against IDO1-expressing immune cells elicits CD8 + and CD4 + T-cell-mediated antitumor immunity and enhanced anti-PD1 responses

Autor: James B. DuHadaway, Erika Sutanto-Ward, Dema Ghaban, Lauren M.F. Merlo, Arpita Mondal, Mads Hald Andersen, Ayako Wakatsuki Pedersen, Laura Mandik-Nayak, Souvik Dey, Katharina L. Kopp, Inés Lecoq, Alexander J. Muller, Mai-Britt Zocca

Publikováno v: Dey, S, Sutanto-Ward, E, Kopp, K L, Duhadaway, J, Mondal, A, Ghaban, D, Lecoq, I, Zocca, M B, Merlo, L M F, Mandik-Nayak, L, Andersen, M H, Pedersen, A W & Muller, A J 2020, ' Peptide vaccination directed against IDO1-expressing immune cells elicits CD8 + and CD4 + T-cell-mediated antitumor immunity and enhanced anti-PD1 responses ', Journal for ImmunoTherapy of Cancer, vol. 8, no. 2, 2020000605 . https://doi.org/10.1136/jitc-2020-000605
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)

BackgroundThe tryptophan-catabolizing enzyme indoleamine 2,3-dioxygenase 1 (IDO1), which subverts T-cell immunity at multiple levels, is itself subject to inherent T-cell reactivity. This intriguing deviation from central tolerance has been interpret

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24213c5586cc584ecdd188e8c7c16e98
https://curis.ku.dk/ws/files/258770834/e000605.full.pdf

SATB1 in Malignant T Cells

Autor: Claudia Nastasi, Tengpeng Hu, Andreas Willerslev-Olsen, Edda Blümel, Terkild B. Buus, Christina Friese, Thorbjørn Krejsgaard, Sergei B. Koralov, Mariusz A. Wasik, Niels Ødum, Jenny L. Persson, Sarah L. Mathiasen, Maria Gluud, Özcan Met, David L. Petersen, Katharina L. Kopp, Linda Kubat, Anders Woetmann, Simon Fredholm, Charlotte M. Bonefeld, Lise M. Lindahl, Jürgen C. Becker, Carsten Geisler, Lars Iversen

Publikováno v: Fredholm, S, Willerslev-Olsen, A, Met, Ö, Kubat, L, Gluud, M, Mathiasen, S L, Friese, C, Blümel, E, Petersen, D L, Hu, T, Nastasi, C, Lindahl, L M, Buus, T B, Krejsgaard, T, Wasik, M A, Kopp, K L, Koralov, S B, Persson, J L, Bonefeld, C M, Geisler, C, Woetmann, A, Iversen, L, Becker, J C & Odum, N 2018, ' SATB1 in Malignant T Cells ', Journal of Investigative Dermatology, vol. 138, no. 8, pp. 1805-1815 . https://doi.org/10.1016/j.jid.2018.03.1526

Deficient expression of Suppressor Special AT-rich Binding-1 (SATB1) hampers thymocyte development and results in inept T cell lineages. Recent data implicate dysregulated SATB1 expression in the pathogenesis of mycosis fungoides (MF), the most frequ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::112ee763f8d53195c47b2a8f72af91e0
https://pubmed.ncbi.nlm.nih.gov/30660670